Alnylam Pharmace. buy Oppenheimer Holdings Inc.
Start price
04.08.25
/
50%
€359.70
Target price
04.08.26
€423.31
Performance (%)
-30.19%
Price
29.07.26
€251.10
This prediction will end soon
Summary
This prediction is currently active. Massive losses of -30.19% have been the result for the BUY prediction by Oppenheimer_Holdings. This prediction currently runs until 04.08.26. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 7.308% | 7.308% |
| iShares Core DAX® | 1,01 % | 2,70 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % |
| iShares S&P 500 | -2,72 % | -1,75 % |
Comments by Oppenheimer_Holdings for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating. They now have a $490.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€361.70
07.01.26
07.01.26
€427.30
07.01.27
07.01.27
-30.58%
29.07.26
29.07.26
